You can probably attribute the use of ritonavir in Medivir’s new trial to the weak results when VRTX combined Incivek and VX-222 without a boosting agent.
How realistic is it for this to ever reach the market given GILD's in-house strategy? Or do you think it'll get used "off-label" when both launch in combo with IFN?
Market Data 
Markets 
